
Opinion|Videos|February 21, 2025
Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL
Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Advertisement
Episodes in this series

- How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement




